GAMMA Investing LLC Boosts Stock Position in Fresenius Medical Care AG (NYSE:FMS)

GAMMA Investing LLC raised its holdings in Fresenius Medical Care AG (NYSE:FMS) by 43.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,164 shares of the company’s stock after buying an additional 2,166 shares during the period. GAMMA Investing LLC’s holdings in Fresenius Medical Care were worth $162,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the business. Wulff Hansen & CO. raised its position in shares of Fresenius Medical Care by 1,809.0% during the 2nd quarter. Wulff Hansen & CO. now owns 343,429 shares of the company’s stock worth $6,556,000 after acquiring an additional 325,439 shares in the last quarter. Moran Wealth Management LLC increased its stake in Fresenius Medical Care by 47.0% in the third quarter. Moran Wealth Management LLC now owns 233,376 shares of the company’s stock valued at $4,971,000 after purchasing an additional 74,621 shares during the last quarter. Quantinno Capital Management LP raised its holdings in Fresenius Medical Care by 78.9% during the third quarter. Quantinno Capital Management LP now owns 110,078 shares of the company’s stock worth $2,345,000 after purchasing an additional 48,554 shares in the last quarter. Crossmark Global Holdings Inc. lifted its position in shares of Fresenius Medical Care by 60.4% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 62,889 shares of the company’s stock worth $1,340,000 after buying an additional 23,692 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Fresenius Medical Care in the 3rd quarter valued at $420,000. 8.37% of the stock is owned by hedge funds and other institutional investors.

Fresenius Medical Care Trading Down 1.2 %

Shares of Fresenius Medical Care stock opened at $22.40 on Thursday. The company’s fifty day moving average is $22.39 and its two-hundred day moving average is $20.73. Fresenius Medical Care AG has a 1 year low of $17.93 and a 1 year high of $24.31. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37. The company has a market capitalization of $13.14 billion, a P/E ratio of 18.51, a PEG ratio of 0.95 and a beta of 0.92.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on FMS shares. StockNews.com began coverage on shares of Fresenius Medical Care in a research note on Friday, January 3rd. They set a “strong-buy” rating on the stock. Truist Financial lifted their target price on Fresenius Medical Care from $23.00 to $25.00 and gave the stock a “hold” rating in a research report on Monday. Bank of America raised Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research report on Monday, December 2nd. Finally, Berenberg Bank began coverage on Fresenius Medical Care in a research report on Wednesday, November 6th. They set a “buy” rating and a $25.60 price target on the stock.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.